Vivosim Labs, INC. quarterly report, Q3 FY2020

Filing identity and reporting period

The provided filing is Organovo Holdings, Inc.’s unaudited Form 10-Q, filed February 10, 2020, for the quarter and nine months ended December 31, 2019 (Organovo fiscal Q3 2020). It does not identify Vivosim Labs, Inc. as the registrant.

Financial results and liquidity

Unless stated otherwise, amounts are in U.S. dollars.

• Nine-month operating cash use was $11.673 million, compared with $15.298 million in the prior-year period. Investing activities provided $0.728 million and financing activities provided $4.935 million, primarily from ATM share sales. Cash, cash equivalents and restricted cash decreased $6.010 million.
• At December 31, cash and cash equivalents were $30.467 million; restricted cash was $0.079 million. Working capital was $28.7 million. Total liabilities were $2.358 million, with no debt balance reported in the presented balance sheet.
• Accumulated deficit was $276.742 million. Stockholders’ equity was $28.954 million.

Changes versus prior comparable periods

• Quarterly revenue fell 62% year over year, to $0.298 million, as service activity declined and product sales were curtailed following the asset sale. Nine-month revenue declined 9%, to $2.196 million.
• Quarterly net loss narrowed to $3.370 million from $6.399 million; nine-month net loss narrowed to $15.987 million from $19.652 million. Lower research and development spending was a principal factor.
• Quarterly R&D expense fell 96% to $0.145 million; nine-month R&D expense fell 48% to $5.413 million. Quarterly SG&A rose 59% to $5.374 million, and nine-month SG&A rose 27% to $15.037 million, reflecting restructuring and merger-related costs, among other items.
• Cash and cash equivalents decreased from $36.477 million at March 31, 2019 to $30.467 million at December 31, 2019. The company raised $5.0 million net through ATM sales in the nine-month period and issued 6.087 million shares through the facility.

Business developments, outlook, and risks

• In August 2019, the board suspended development of the lead liver therapeutic program and other related pipeline work, citing development challenges, lengthy redevelopment timelines, and resource constraints. The company said historical results were not indicative of future results.
• Organovo sold certain Samsara Sciences equipment and inventory to LifeNet Health for $1.5 million and exited its main facility lease effective November 15, 2019, recording a $0.525 million lease-termination gain. It terminated 52 employees, about 90% of its workforce, leaving six general and administrative personnel.
• On December 13, 2019, Organovo agreed to merge with private biopharmaceutical company Tarveda Therapeutics. The filing anticipated completion in fiscal Q4 2020, subject to customary conditions, including Organovo stockholder approval of the share issuance and a reverse stock split. Tarveda holders were expected to own about 75% of the combined company on a fully diluted basis and Organovo holders about 25%, subject to agreement adjustments.
• The exchange ratio adjusts based on Organovo’s net cash at closing: below $22 million, Tarveda holders may receive more shares; above $22 million, they may receive fewer. If Tarveda’s closing net cash is below $15 million, Organovo may elect not to close. The January 2020 amendment provides a $1.5 million valuation credit to Organovo if it retains its intellectual property and remaining assets through closing.
• Management expected approximately $4.2 million of transaction-related costs and potentially $3.5 million of additional severance costs tied to the merger. It projected approximately $29.0 million cash at fiscal year-end absent further asset-sale, legal, merger, or severance impacts. It stated current resources were expected to support the current operating plan for at least 12 months, while also disclosing substantial doubt about the company’s ability to finance itself on a long-term basis.
• Nasdaq had notified the company that its share price failed the $1 minimum bid requirement. Organovo obtained an additional 180-day compliance period after transferring to the Nasdaq Capital Market; failure to regain compliance could lead to delisting and affect the merger.
• Legal matters included a dismissed putative class action, a stockholder books-and-records demand, and a January 2020 demand letter alleging deficiencies in merger disclosures. The company said it considered the letter’s assertions without merit and recorded no loss contingency accrual; outcomes remain uncertain.

Most important facts to verify

1. Confirm the registrant and period: this filing is for Organovo Holdings, Inc., quarter ended December 31, 2019, not a filing identified as Vivosim Labs, Inc. or 2019 Q3.
2. Check the merger’s final status, closing net-cash calculations, exchange-ratio adjustments, stockholder approvals, and reverse-split terms; the filing’s merger outlook was forward-looking.
3. Reconcile the expected cash runway and projected $29.0 million year-end balance against transaction costs, severance, continuing corporate expenses, and any additional asset sales or legal costs.
4. Assess Nasdaq listing compliance, potential dilution and termination fees if the merger fails, and the company’s stated possibility of an alternative transaction or wind-down.
5. Review the full notes and subsequent filings for developments in litigation, restructuring obligations, and the valuation or impairment of remaining assets.